生物医药项目融资难一直是制约整个产业发展的主要问题之一,目前这一难题是否有所缓解?出现了什么新的动向?作为生物技术研发与创新的聚集地,中关村生命科学园是如何看待这一问题的?园区在完善产业链条,促进成果转化方面有哪些进展?而入园企业又面临着哪些普遍的问题和困惑呢? Biopharmaceutical project financing difficulty has been one of the main problems restricting the development of the entire industry. At present, whether this problem has eased? What new trends have emerged? As a gathering place for biotechnology R & D and innovation, how does Zhongguancun Life Science Park look? This problem? Park to improve the industrial chain, to promote the achievement of what progress has been made? And admission enterprises are facing what the general problems and confusion?